{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:35:34Z","timestamp":1767792934103,"version":"3.49.0"},"reference-count":32,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"unspecified","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Astra Zeneca","award":["Freely sponsoring drugs"],"award-info":[{"award-number":["Freely sponsoring drugs"]}]},{"DOI":"10.13039\/100013986","name":"UK Government","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013986","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["NIHR302418"],"award-info":[{"award-number":["NIHR302418"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institute for Health"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,10,19]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Asthma is the most common non-communicable disease among children, with increasing prevalence. The current standard of care in high-income countries in adults and adolescents includes the use of combination inhaled corticosteroids (ICSs) with rapid-onset long-acting \u00df\n                      <jats:sub>2<\/jats:sub>\n                      agonists (LABA) for all severities of asthma. The primary objective of this trial is to assess the efficacy of a budesonide\/formoterol inhaler used \u2018both as required, and regularly\u2019 to reduce asthma exacerbations compared with the standard of care for asthma in children and adolescents.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Children and adolescents aged 6\u201318 years with a diagnosis of asthma with at least one asthma exacerbation in the previous 12 months will be randomised to receive either budesonide\/formoterol inhaler or the standard of care, which includes ICS and short-acting \u00df\n                      <jats:sub>2<\/jats:sub>\n                      agonist (SABA). The primary outcome will be the number of severe asthma exacerbations over 1-year follow-up period. Secondary objectives will include evaluating the quality of life, lung function and health economic outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The current standard of care in South Africa recommends use of separate ICSs and SABA inhalers for asthma management in children with no recommendation for ICS\/LABA in children under the age of 12 years for non-severe asthma. Budesonide\/formoterol has transformed asthma treatment in high-income countries for use \u2018as needed\u2019 as anti-inflammatory reliever and for maintenance and reliever in adolescence, 12\u221218 years and adults. This strategy has been shown to reduce asthma exacerbations and hospitalisations. This trial will bridge the gap for the efficacy of budesonide\/formoterol in children &lt;12 years of age and address the economic arguments and safety of this approach for implementation in the lower to middle income countries. If this trial demonstrates positive results in the study population, it could provide strong scientific evidence and policy relevance to be adopted by policymakers for clinical implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      This study has been registered and approved by the South African Health Regulatory Authority 20231016, on 14 December 2023, KwaZulu Natal Health Research Committee KZ_202304_008 on 11 January 2024, University of KwaZulu Natal Biomedical Research Ethics Committee BREC\/0000\/5663\/2023 on 6 February 2024, South African Clinical Trials Register DOH-27-032024-4778 on 14 March 2024, ClinicalTrial.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06429475\">NCT06429475<\/jats:ext-link>\n                      on 20 May 2024 and Pan African Clinical Trial Registry on 27 February 2025; the unique identification number for the registry is PACTR202502547023775.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003378","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T07:40:24Z","timestamp":1763451624000},"page":"e003378","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-inflammatory reliever therapy for asthma using inhaled budesonide\/formoterol as-needed with or without maintenance in South African children (AIR-SA 001): a description of a randomised clinical trial protocol"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct06429475","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06429475","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8183-7977","authenticated-orcid":false,"given":"ST","family":"Hlophe","sequence":"first","affiliation":[{"name":"Department of Paediatrics and Child Health, College of Health Sciences University of KwaZulu Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NN","family":"Ndimande","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, College of Health Sciences University of KwaZulu Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Ngobese","sequence":"additional","affiliation":[{"name":"Africa Health Research Instutute, Somkhele, Kwazulu Natal, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Mkwanazi","sequence":"additional","affiliation":[{"name":"Africa Health Research Instutute, Somkhele, Kwazulu Natal, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Bird","sequence":"additional","affiliation":[{"name":"Africa Health Research Instutute, Somkhele, Kwazulu Natal, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Mbonigaba","sequence":"additional","affiliation":[{"name":"University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Otwombe","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Lebina","sequence":"additional","affiliation":[{"name":"Africa Health Research Instutute, Somkhele, Kwazulu Natal, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Mortimer","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, College of Health Sciences University of KwaZulu Natal, Durban, South Africa"},{"name":"Respiratory Medicine, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9665-2035","authenticated-orcid":false,"given":"R","family":"Masekela","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, College of Health Sciences University of KwaZulu Natal, Durban, South Africa"},{"name":"Africa Health Research Instutute, Somkhele, Kwazulu Natal, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2026010701515325000_12.1.e003378.1","unstructured":"Global_Asthma_Report_2018, Available: http:\/\/globalasthmareport.org\/. Global_Asthma_Report_2018"},{"key":"2026010701515325000_12.1.e003378.2","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00576-2020","article-title":"Asthma in South African adolescents: a time trend and risk factor analysis over two decades","volume":"7","author":"Baard","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026010701515325000_12.1.e003378.3","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2013.54.519"},{"key":"2026010701515325000_12.1.e003378.4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S2213-2600(21)00135-1","article-title":"Treatment of mild-to-moderate asthma in childhood and adolescence in 2021","volume":"9","author":"Abrams","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026010701515325000_12.1.e003378.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715274"},{"key":"2026010701515325000_12.1.e003378.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715275"},{"key":"2026010701515325000_12.1.e003378.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901963"},{"key":"2026010701515325000_12.1.e003378.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31948-8"},{"key":"2026010701515325000_12.1.e003378.9","article-title":"Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children","volume":"2013","author":"Kew","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010701515325000_12.1.e003378.10","doi-asserted-by":"crossref","unstructured":"Cates CJ , Karner C . Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev 2016;2016. doi:10.1002\/14651858.CD007313.pub3","DOI":"10.1002\/14651858.CD007313.pub3"},{"key":"2026010701515325000_12.1.e003378.11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(13)70012-2","article-title":"Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial","volume":"1","author":"Papi","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026010701515325000_12.1.e003378.12","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1016\/j.jaip.2021.04.016","article-title":"Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma","volume":"9","author":"Reddel","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026010701515325000_12.1.e003378.13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.6.1733"},{"key":"2026010701515325000_12.1.e003378.14","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaip.2024.01.011","article-title":"The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today","volume":"12","author":"Krings","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026010701515325000_12.1.e003378.15","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.1016\/S2214-109X(22)00330-8","article-title":"The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review","volume":"10","author":"Stolbrink","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2026010701515325000_12.1.e003378.16","unstructured":"Global Strategy for Asthma Management and Prevention, 2024. Available: https:\/\/ginasthma.org"},{"key":"2026010701515325000_12.1.e003378.17","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00271-2021","article-title":"The Children\u2019s Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma","volume":"7","author":"Hatter","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026010701515325000_12.1.e003378.18","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00897-2023","article-title":"START CARE: a protocol for a randomised controlled trial of step-wise budesonide-formoterol reliever-based treatment in children","volume":"10","author":"Barry","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026010701515325000_12.1.e003378.19","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00293-2021","article-title":"Clinical value of bronchodilator response for diagnosing asthma in steroid-na\u00efve adults","volume":"7","author":"Tuomisto","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026010701515325000_12.1.e003378.20","unstructured":"NICE . Asthma: diagnosis, monitoring and chronic asthma management. London: National Institute for Health and Care Excellence (NICE); 2021 Mar 22. (NICE Guideline, No. 80.), 2021. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560178"},{"key":"2026010701515325000_12.1.e003378.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200801-060ST"},{"key":"2026010701515325000_12.1.e003378.22","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"2026010701515325000_12.1.e003378.23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/sim.5947","article-title":"Sample size calculation for comparing two negative binomial rates","volume":"33","author":"Zhu","year":"2014","journal-title":"Stat Med"},{"key":"2026010701515325000_12.1.e003378.24","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.95.08030483"},{"key":"2026010701515325000_12.1.e003378.25","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1002\/sim.7077","article-title":"Multi-arm group sequential designs with a simultaneous stopping rule","volume":"35","author":"Urach","year":"2016","journal-title":"Stat Med"},{"key":"2026010701515325000_12.1.e003378.26","unstructured":"South African Good Clinical Practice: Clinical Trial Guidelines, Available: www.sahpra.org.za\/wp-content\/uploads\/2021\/06\/SA-GCP-2020_Final.pdf"},{"key":"2026010701515325000_12.1.e003378.27","doi-asserted-by":"crossref","unstructured":"Hatter L , Bruce P , Braithwaite I , et al . ICS-formoterol reliever versus ICS and short-acting \u03b2(2)-agonist reliever in asthma: a systematic review and meta-analysis. ERJ Open Res 2021;7. doi:10.1183\/23120541.00701-2020","DOI":"10.1183\/23120541.00701-2020"},{"key":"2026010701515325000_12.1.e003378.28","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-884OC"},{"key":"2026010701515325000_12.1.e003378.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69284-2"},{"key":"2026010701515325000_12.1.e003378.30","article-title":"Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma","volume":"5","author":"Crossingham","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010701515325000_12.1.e003378.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001498","article-title":"Prevalence, severity and risk factors for asthma in school-going adolescents in KwaZulu Natal, South Africa","volume":"10","author":"Mphahlele","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"2026010701515325000_12.1.e003378.32","unstructured":"Safety Reporting During Clinical Trials In SOUTH AFRICA, Available: https:\/\/www.sahpra.org.za\/wp-content\/uploads\/2021\/10\/Safety-Reporting-During-Clinical-Trials_-August-2021_V4.pdf"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:53:16Z","timestamp":1767779596000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,17]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjresp-2025-003378"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003378","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}